ACP
XFOR icon

Acuta Capital Partners’s X4 Pharmaceuticals XFOR Stock Holding History

Acuta Capital Partners’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,333
Closed -$428K – 40
2019
Q4 		$428K Buy
+1,333
New +$478K 0.11% 38

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Acuta Capital Partners's XFOR Position: Q1 2020 in Review

Acuta Capital Partners sold out of X4 Pharmaceuticals (XFOR) in Q1 2020, closing a stake of 1,333 shares — an estimated $428K sold.

Acuta Capital Partners first reported a position in XFOR in Q4 2019 and held it in 1 quarter. The position peaked at $428K in Q4 2019. 50 funds tracked by Wall St. Rank hold XFOR as of Q1 2020.

  • Acuta Capital Partners reported no remaining X4 Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 1,333 X4 Pharmaceuticals shares in Q1 2020, an estimated $428K.
  • Acuta Capital Partners first reported a position in X4 Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Acuta Capital Partners's X4 Pharmaceuticals position peaked at $428K in Q4 2019.
  • 50 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2020.

Based on Acuta Capital Partners's 13F filing for Q1 2020, filed 15 May 2020.